The insider sales are routine post-exercise diversification by non-executive directors and are immaterial relative to market cap. No C-suite selling or cross-filing red flags exist. Monitor for any C-suite open-market sales or a material increase in selling volume above 0.1% of market cap, which would warrant a more bearish read.
BBIO drugs
BBIO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 14 $84.09entry
- T+1 · 4mo ago −1.70%α −2.10% · $82.66
- T+5 · 4mo ago −1.95%α −1.48% · $82.45
- T+20 · 3mo ago −0.46%α −2.96% · $83.70
- T+60 · 6w ago −20.92%α −24.30% · $66.50
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two BridgeBio directors executed open-market sales totaling $11.56M on July 9, 2026, following derivative exercises. Director Cook sold $10.12M at $90/share and Director Ellis sold $1.44M at $84/share. The sales represent ~0.07% of the $16.3B market cap, falling below the 0.1% materiality threshold, and are consistent with routine post-exercise diversification. No C-suite executives participated, and the cluster is not amplified by any cross-filing context that would suggest informed selling.
Key Financial Metrics
Key Facts
- Two directors (Cook and Ellis) sold a combined $11.56M in open-market transactions on July 9, 2026
- Director Cook sold 112,422 shares at $90/share ($10.12M) and 36,167 shares at $84/share ($3.04M)
- Director Ellis sold 17,167 shares at $84/share ($1.44M)
- All sales followed derivative exercises at prices between $0 and $29/share, generating non-cash gains
- Total open-market sales represent ~0.07% of BridgeBio's $16.3B market cap
- No C-suite executives (CEO, CFO, COO) participated in the cluster
- No 10b5-1 plan designation was noted in the filings
- The cluster is not accompanied by any earnings, restructuring, or late-filing context that would amplify its significance
Financial Impact
Total open-market sales of $11.56M, representing ~0.07% of market cap, below the 0.1% materiality threshold for insider clusters
Risk Factors
- Insider selling could accelerate if the stock continues to appreciate, but current levels are not alarming
- Derivative exercises add to public float, though the ~149K shares exercised are negligible for a $16.3B company
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BBIO-1784009308941 |
Track record
38 reports on BBIO
10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.
Filters
- Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
- Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
- Oct 29, 202618d ago 8-K Bullish 6/10 No price data
- Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
- Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
- Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
- Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
- Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
- Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers